|Bid||4.1300 x 1800|
|Ask||4.2900 x 1300|
|Day's Range||4.0650 - 4.2700|
|52 Week Range||1.7400 - 5.5000|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. Eastern Time.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies.
Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?